Characterization of peripheral and cerebral L-3,4-dihydroxy-6-[ 'SF]fluorophenylalanine (FDOPA) metabolism in humans and monkeys has shown FDOP A to be an analogue of L-DOPA for the study of the dopa minergic system with positron emission tomography (PET). In human studies with carbidopa pretreatment, L-3 ,4-dihydroxy-6-[ 'SF]fluoro-3-0-meth ylpheny lalanine (3-0MFD) was the only FDOPA metabolite detected in plasma. FDOPA administration in monkeys resulted in selective accumulation of FDOP A metabolites in central dopaminergic regions, whereas 3-0MFD of peripheral or-
igin was uniformly distributed among putamen, caudate, frontal cortex, and cerebellum. At 60 min, 3-0MFD and 6-[,sF]fluorodopamine (FDA) each represented -35% of the total activity, the remainder being FDOPA and FDA metabolites. These data on monkey and human FDOPA metabolism provide the basis for the configuration of an FDOPA tracer kinetic model with PET. Key Words: Basal ganglia-L-3,4-Dihydroxy-6-[ 'SF]fluorophenylalanine Dopamine-Monkey brain-Positron emission tomogra phy. rodopamine (FDA) by aromatic amino acid decarboxylase (EC 4. ] .1.28) and subsequently that of FDA to its metabolites 3,4-dihydroxy-6-[lsF]fluorophenylacetic acid (FDOPAC) and 6-esF]fluorohomovanillic acid (FHV A) (Firnau et al., 1987; Melega et al., 1990a) . In FDOPA PET studies of Parkinson's disease (Nahmias et al., 1985; Leenders et al. , 1986) , 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure in both humans and nonhuman primates (CaIne et al., 1985; Doudet et al. , 1989) , and other extrapyramidal disorders (Brooks and Frackowiak, 1989) , reduc tions in tracer accumulation have provided a qual itative index of the integrity of the dopaminergic system. However, the PET method with its dy namic, real-time acquisition of kinetic data can also produce a quantitative assessment of tracer flux upon fitting of the radioactivity measurements to a kinetic model of FDOPA metabolism. This model includes plasma and tissue compartments together with rate constants for transfer of plasma FDOPA to tissue, FDA synthesis, and FDA metabolite clearance. Data necessary for that model configu ration can be derived only from animal and human biochemical studies of FDOPA metabolism. Therefore, interpretation of human FDOPA me tabolism with PET requires a quantitative kinetic model that incorporates the following: characteriza tion and quantification of FDOPA metabolites in plasma, determination of the extent of metabolite entry into brain, and characterization of specific ac cumulation in brain that can be attributed to FDA and its functional metabolites.
FDOPA peripheral metabolism has been bio chemically characterized in rats (Cumming et aI ., 1987; Melega et aI., 1990a) , monkeys (Melega et aI ., 1990b) , and humans (Boyes et aI., 1986; Melega et aI., 1990b) . The major peripheral metabolite de tected in plasma was L-3,4-dihydroxy-6-e8F]fluoro-3-0-methylphenylalanine (3-0MFD). Carbidopa pretreatment increased FDOPA bioavailability to brain (Hoffman et aI., 1989) , while it limited periph eral FDOPA metabolism to 3-0MFD .
FDOPA cerebral metabolism has also been char acterized in rats (Cumming et aI., 1987; Melega et aI., 1990a) and in monkeys (Firnau et aI., 1987) . Those results indicated that FDA was the major FDOPA metabolite formed in striatum, although in the rat studies a similar quantity of the peripheral metabolite 3-0MFD was present. Relatively lower levels of the FDA metabolites FDOPAC and FHVA were also observed. In contrast, cerebellum activity consisted of FDOPA and 3-0MFD, accumulation and clearance being proportional to their plasma levels and respective partition coefficients between plasma and brain .
Although rat studies have contributed valuable data on FDOPA metabolism, primate studies are also necessary. Peripheral and cerebral metabolism analyses in monkeys provide data that can validate the use of rats as models for primate cerebral FDOPA metabolism. Also, the same monkey can receive an in vivo FDOPA PET scan and, at a later date, be administered FDOPA exclusively for bio chemical analysis. In this manner, 18F cerebral ki netics determined with PET can be directly corre lated with central FDOPA metabolite levels at se lected time points.
We present in this work biochemical data on pe ripheral FDOPA metabolism in monkeys and hu mans and on cerebral FDOPA metabolism in mon keys that provide the basis for the development of an FDOPA PET tracer kinetic model. The mathe matical model and its validation with PET are pre sented in the companion article.
METHODS

Monkeys
Macaca nemestrina monkeys (5-7 kg; n = 3) were anesthetized with ketamine (10 mg/kg) followed by so dium pentobarbital (20 mg/h). Carbidopa was adminis tered (5 mg/kg i. v.) 60 min prior to FDOPA injection (5-8 mCi i. v.; specific activity 1-2 Ci/mmol). Prior to death, heparinized blood samples were obtained and centrifuged in a microfuge at 4°C for plasma separation. To the plasma was added an equal volume of cold solution con taining 0.8 M perchloric acid, 1.0% Na2S20S' and 0.2% ethylenediaminetetraacetate (EDT A); the resulting sus pension was centrifuged and filtered (pore size 0.2 /J-m) before HPLC analysis. The monkeys were then killed by an overdose of sodium pentobarbital (100 mg/kg i.v.,); brains were removed (-30 min) and regions of interest were dissected on an ice-chilled aluminum plate, im mersed in liquid nitrogen, and subsequently weighed and counted for total activity. Brain samples were then ho mogenized in 0.5 ml of a cold solution containing 0.4 M perchloric acid, 0.5% Na2S20S' and 0.1 % EDT A and pro cessed for HPLC analysis as indicated above for plasma samples. Extraction of 18F-metabolites from plasma was essentially quantitative, while that of 18F-metabolites and endogenous catecholamines from brain tissues was >85%.
Humans
Prior to the study, normal male volunteers (20-30 years; n = 6) signed informed consent forms and the experimental protocol was approved by the UCLA Hu man Subject Protection Committee. Subjects were fasted for at least 6 h prior to the study; carbidopa (200 mg p.o.) was administered 90 min prior to FDOPA injection (4-8 mCi) via an intravenous catheter. Blood samples (2.5 m!)
were obtained with a radial artery catheter at 2, 4, 5, 10, 20, 30, 60, and 90 min and were processed as described above for monkeys.
Analytical methods
The HPLC system consisted of a Beckman 210 solvent delivery system with the following mobile phase for plasma analysis: 80% 0.1 M NaH2P04, 1.7 mM (2.3 mM for brain samples) octane sulfonic acid sodium salt, 0.1 mM EDTA, pH 3.1 (pH 3.3 for brain samples), and 20% MeOH at a flow rate of 1 ml/min. A guard cell (+0.45 V; ESA) preceded a Rheodyne 7125 injector fitted with a 100-/J-l loop. A guard column (30 x 4.6 mm, 5 /J-m; Brown lee) was used in conjunction with a CI 8 reverse phase column (250 x 4.6 mm, 5 /J-m; Beckman). The analytical cell (model 5011; ESA) was set at an applied potential of + 0.02 V (detector 1) and + 0.4 V (detector 2) and coupled to a coulochem controller (model 5100A; ESA) to monitor endogenous catecholamine and carbidopa levels. Frac tions (\ mllmin) were collected and counted for radioac tivity (decay corrected) in an NaI well counter. Radioac tivity peaks were identified by comparison of their reten tion times with those of authentic metabolite standards (Luxen and Barrio, 1988) . Those peaks were FDOPA, 3-0MFD, FDA, FDA sulfate, FDOPAC, and FHVA.
Materials
Octane sulfonic acid was purchased from Kodak; all other reagents were from Fisher Scientific. L-u H ydrazino-u -meth y \-13-(3, 4-dih ydroxyphen y l)propionic acid (carbidopa) was a gift of Merck, Sharpe and Dohme. FDOPA (spec activity, 1-2 Ci/mmol) was prepared by using the radiofluorodemercuration procedure previously described (Luxen et al., 1986; Luxen and Barrio, 1988) .
RESULTS
Cerebral FDOPA metabolism in monkeys
At 60 min after FDOPA administration, FDOPA metabolites ( Fig. 1) were quantitated for putamen,
caudate, fr ontal cortex, and cerebellum of monkeys (mean ± SD, n = 3). FDA was detected only in caudate and putamen (Fig. 1) , and in each region it represented � 35% of the total radioactivity, while FDA metabolites FDOPAC and FHVA each repre sented � 10% . In frontal cortex � 5% of the activity appeared as FHVA ( Fig. 2A) .
The major FDOPA metabolite detected in all brain areas was 3-0MFD. This metabolite repre sented �35% of the total activity in putamen and caudate. In cortex and cerebellum (Fig. 2 3-0MFD accounted for �80% of the activity, the remainder consisted of FDOPA and FDA sulfate. Tissue/cerebellum 3-0MFD ratios (range 0.80-0.87) were derived from the counts per gram/millicuries per kilogram) values for each region (Table 1) .
The levels of dopamine and its metabolites (Table  2) were also determined (mean ± SD, n = 3) and presented for comparison with their 18F analogues.
FDOPA metabolites in plasma
In monkeys, the plasma FDOPA metabolite pro file at 60 min (Fig. 3) 
FDOPA, 3-0MFD, and FDA sulfate. 3-0MFD rep resented 63% of the total activity, while FDOPA and FDA sulfate accounted for 25 and 10%, respec tively; FDOPAC and FHVA were present in trace amounts. The presence of FDA metabolites was in dicative of incomplete decarboxylase inhibition with carbidopa. It has been observed that monkeys have high levels of aromatic amino acid decarbox ylase (Lloyd and Hornykiewicz, 1972) for which complete inhibition of the peripheral enzyme with carbidopa is unlikely. In humans, carbidopa (200 mg p.o.) was admin- Values were derived from measurements (mean ± SD, n = 3) obtained 60 min after FDOPA administration. No significant differences were ob served among brain regions (t-test, p > 0.05) istered 90 min prior to FDOPA injection. Plasma levels (data not shown) ranged from 0.35 ± 0.18 J.Lg/ml (mean ± SD, n = 6) at the time of FDOPA injection to 0.25 ± 0.15 J.Lg/ml at 90 min. Peripheral metabolism as detected in plasma was restricted to 3-0MFD formation, and this metabolic pathway ac counted for �60% of the total plasma activity by 60 min (Fig. 4) .
DISCUSSION
Quantitative evaluation of FDOPA PET studies requires tracer kinetic models that are configured to peripheral and cerebral FDOPA metabolism. Re cent results on peripheral FDOPA metabolism have demonstrated that FDOPA is metabolized to FDA, FDA sulfate, FDOPAC, FHVA, and 3-0MFD, the latter being capable of entering the brain (Cumming et aI., 1987 (Cumming et aI., , 1988 Comi et aI., 1989; Melega et aI., 1990a; Reith et aI., 1990; Dejesus et aI., 1991) . These findings, however, are at variance with ear lier studies on O-methylation of FDOPA. Those re sults indicated that 3-0MFD was not a significant metabolite of FDOPA in human plasma (Firnau et aI., 1988) . Mechanistic arguments had also been presented to explain the low rate in vitro ofFDOPA 3-0-methylation by catechol-O-methyltransferase (EC 2. 1.1.6) (Kirk and Creveling, 1984; Creveling and Kirk, 1985) . However, the preferential and in creased 3-0-methylation of FDOPA relative to that of L-DOPA can be attributed to the effect of fluorine substitution on the phenolic 3-0H group stabiliza tion as its phenoxide ion (Melega et aI., 1990a) .
Our results on human peripheral FDOPA metab- olism as detected in plasma (200 mg carbidopa, 90 min pre FDOPA injection) demonstrated sufficient inhibition of peripheral decarboxylase activity inso far as FDA and any of its subsequent metabolites (e.g., FDA sulfate, FDOPAC, and FHVA) were not detected. Thus, FDOPA metabolism was essen tially restricted to 3-0MFD. Lower doses of carbi dopa (100 mg, 60 min pre FDOPA) result in incom plete inhibition of decarboxylase activity with for mation of FDA sulfate and FHV A at later times (Melega et aI., 1990b) . Therefore, in human FDOPA studies with carbi dopa pretreatment (200 mg), 3-0MFD is the only peripheral FDOPA metabolite that can enter the brain. Its uniform distribution in monkey brain was indicated by the similar 3-0MFD levels observed at 60 min in various regions. Although no significant differences were found (Table 1) , the slightly higher cerebellum levels of 3-0MFD may have been the result of postmortem artifacts. Partial local tissue formation of 3-0MFD during brain sample process ing (�30 min) probably occurred owing to relatively high levels of catechol-O-methyltransferase in var ious brain structures (Park, 1986) . Other PET stud ies in primates with 3-0MFD as a tracer have indi cated its uniform distribution in brain tissue (Doudet et aI., 1990) , in accordance with results from previous studies in rats (Melega et aI. , 1990a) .
With FDOPA, selective accumulation and reten tion of 18F-activity observed in dopaminergic re gions are the consequence of local FDOPA decar boxylation to FDA. The extent of this accumulation has been used as an index of endogenous decarbox ylase activity (Martin et aI., 1989) . Moreover, since FDOPA metabolism parallels that of exogenous L-DOPA, metabolism of FDOPA to FDA is fol lowed by further conversion to FDOPAC and FHVA (Melega et aI., 1990a) . The subsequent clearance of these latter two metabolites from brain can then be associated with functional activity and allows for FDA turnover rates to be estimated from PET kinetics. However, FDA synthesis and its me tabolism bypass the proposed rate-limiting step of dopamine synthesis imposed by tyrosine hydroxy lase (Masserano and Weiner, 1983) , and therefore FDOPA metabolic rates may not be necessarily cor related with those of the endogenous dopamine sys tem. For example, other tracer studies in catechol amine-innervated tissues have shown that stimula tion of sympathetic output effected increases in labeled norepinephrine only with [14C]tyrosine as precursor but not with eH]DOPA (Gey and Pletscher, 1968; Weiner and Rabadjija, 1968) .
Our studies on FDOPA biochemical characteriza tion in monkey brain indicated that FDA was the major metabolite detected from striatal FDOPA me tabolism at 60 min. The persistence of relatively high FDA levels in striatum 1 h after FDOPA ad ministration indicated that FDA had entered into a slow turnover rate pool of dopamine. A similar rate of FDA metabolism has been characterized in rat striatum in which FDA levels decreased only 20% between 15 and 60 min after FDOPA administration (Melega et aI., 1990a) . At present, FDOPA PET studies have focused only on densely innervated dopamine terminal ar eas such as caudate and putamen. However, the presence of dopaminergic terminals has been iden tified in both monkey and human cortex (Berger et aI., 1988; Gaspar et aI., 1989) . In the present work, HV A levels in frontal cortex were observed in the absence of FDA and FDOPAC, suggestive of an increased FDA turnover rate relative to that for caudate and putamen. Although various brain re gions in primates have not been characterized, such
FIG. 4. Percentage of total radioactivity versus time for FDOPA and 3-0MFD in human plasma (mean ± SD, n = 6). Other FDOPA metabolites were not detected. studies in rats have shown dopamine turnover for frontal cortex to be two to four times faster than that for striatum (Bannon et aI., 1981) . The differences between FDOPA metabolite pro files for caudate-putamen and cortex are suggestive of relative differences in FDOPA turnover in pri mate. However, these differences need to be accu rately characterized in primate biochemical studies that can provide activity-time profiles for FDA me tabolism and clearance of its metabolites. Those data can provide validation for quantitation of FDA turnover determined with PET.
Although issues of FDA compartmentation and FDA turnover have not been resolved, it is clear that FDOPA enters into a functional component of dopamine metabolism. It has been demonstrated that FDA is stored in vesicles and can be subse quently released upon stimulation (Chiueh et aI., 1983) . Furthermore, recent work with FDOPA in MPTP-treated monkeys (Melega et aI., 1991) has shown parallel changes between FDOPA and dopa mine metabolism. That is, after FDOPA administra tion to MPTP-treated monkeys, FDA levels in puta men were essentially reduced to trace amounts, while endogenous dopamine levels were also signif icantly lowered (2% of controls). Moreover, the amines and their respective metabolite FHV A/FDA and HV AIDA ratios were both similarly increased. Such parallel changes in the MPTP-treated mon keys were suggestive of increased turnover of both FDA and dopamine and indicated a rapid utilization of the available precursors for neurotransmitter synthesis.
Therefore, while the significance of a quantitative correlation between exogenous FDOPA as a tracer and endogenous dopamine stores remains to be de termined in normal primates, the MPTP results in dicate that for diseases of the basal ganglia, changes observed for FDA metabolism will parallel those of endogenous dopamine. Such quantitative measures of FDOPA metabolism will be of significant value for longitudinal studies (e.g., effects of drug treat ment in Parkinson's disease, pre-and posttrans plant effects). Also, differences in regional FDA flux within dopaminergic structures (e.g., dorsal and ventral striatum) may be delineated with the improved resolution of new PET instrumentation.
In conclusion, these results establish the bio chemical basis for a kinetic model of FDOPA me tabolism as measured with PET. Specifically, the constraints used in the model formulation are now biochemically defined. (a) Only FDOPA and 3-0MFD can enter the brain. Carbidopa pretreat ment restricts peripheral FDOPA metabolism to 3-0MFD and thereby eliminates the peripheral for-J Cereb Blood Flow Metab, Vol. 11, No.6, 1991 mation of other nonspecific metabolites that can en ter the brain. (b) The distribution volume for 3-0MFD is close to 1, for which its contribution to striatal radioactivity can be easily estimated. (c) The FDOPA decarboxylation rate can be calcu lated. The high levels of FDA synthesized and re tained in dopaminergic brain regions provide a rel ative index of cell function. Furthermore, FDOPA metabolite quantitation allows for validation of model predictions of the relative biochemical com ponents of brain activity observed with PET. (d) FDA turnover is relatively slow in normal brain. To the extent that FDA release and metabolism occur, turnover measurements can be derived from the clearance of FDOPA metabolites from brain. These issues are developed in the companion article, by Huang et al. (1991) which presents the theory and validation of an FDOPA model with PET.
